Tranexamic Acid Melasma Trial: 12-Week Oral vs Topical Comparison Validates Both Options
SKIN

Tranexamic Acid Melasma Trial: 12-Week Oral vs Topical Comparison Validates Both Options

By Sophie · · https://onlinelibrary.wiley.com/doi/10.1111/jocd.70428
KO | EN

A randomized trial directly comparing oral tranexamic acid and topical tranexamic acid, the two core melasma treatment options, was published in Journal of Cosmetic Dermatology. In 12-week comparison, oral was slightly superior but both options validated meaningful effect and safety.

Trial design

Participants: 50 melasma patients. Single-center randomized trial.

Intervention: Oral tranexamic acid 250 mg twice daily or topical 5% tranexamic acid cream twice daily.

Duration: 12 weeks.

Primary endpoint: mMASI (Modified Melasma Area and Severity Index).

Core results

MASI reduction (mean):

  • Oral tranexamic acid: -58.86%
  • Topical tranexamic acid: -50.88%

Oral about 8 percentage points superior: Statistically significant but both options clinically meaningful improvement.

Side effects: Both options mild. Topical: irritation, itching. Oral: some GI discomfort.

Patient satisfaction: High in both groups.

Quality of life indicators: Meaningful improvement in both groups.

Tranexamic acid and melasma mechanism

What is tranexamic acid: Synthetic lysine analog. Originally developed as bleeding control drug. Melasma effect discovered serendipitously.

Plasmin inhibition: Suppresses plasmin activity in keratinocytes. Plasmin mediates melanocyte stimulation.

Arachidonic acid pathway blocking: Partial blockade of UV-induced melanocyte activation pathway.

MITF reduction: Partial reduction of melanocyte differentiation transcription factor.

Vascular targeting: Also affects vascular changes accompanying melasma.

Different mechanism from traditional brightening ingredients (hydroquinone, azelaic acid, kojic acid). Synergy possible.

Oral vs topical choice

Oral option fits:

  • Widespread melasma
  • Topical irritation sensitivity
  • Physician monitoring possible
  • Faster results targeting
  • Lower cost burden

Topical option fits:

  • Localized melasma
  • Pregnancy/breastfeeding (avoid oral)
  • Drug interaction concerns
  • Difficult physician prescription situations
  • Side effect avoidance

Matrix with other treatments

Niosomal tranexamic acid + niacinamide: A Scientific Reports trial published the same period. Niosomal-encapsulated 2% tranexamic acid + 2% niacinamide showed similar effects to standard 5% + 4% or hydroquinone 4%. Encapsulation technology validated effects at lower concentrations.

Hydroquinone 4%: Traditional gold standard. Avoid 4+ months use due to irritation and ochronosis risk (paradoxical pigmentation).

Azelaic acid 20%: A trial published the same period showed 24-week application meaningfully reduced pigmentation intensity in dark-skinned (Fitzpatrick IV~VI) populations.

Alpha-arbutin + kojic acid: Other options the same quarter.

Procedural options: PicoSure, Q-switched lasers, microdermabrasion synergize with tranexamic acid.

UV protection: Foundation of all melasma treatment. SPF 30+ daily.

Safety profile

Oral tranexamic acid cautions:

  • VTE risk (avoid with personal/family history)
  • Avoid in pregnancy/breastfeeding
  • Caution with anticoagulants
  • Physician evaluation in kidney disease
  • Visual changes (rare)
  • Drug interactions (contraceptives, hormone replacement)

Topical tranexamic acid cautions:

  • Irritation, itching
  • Allergic reaction (rare)
  • Limited safety data in pregnancy/breastfeeding
  • Increased irritation with other topicals

Melasma matrix

Layer 1 — foundation: UV protection (SPF 30+, daily, broad spectrum).

Layer 2 — irritation avoidance: Avoid harsh exfoliation, aggressive procedures.

Layer 3 — topical: Tranexamic acid topical 5% or hydroquinone 4% or azelaic acid 20% or alpha-arbutin.

Layer 4 — oral: Tranexamic acid 250 mg twice daily for 12 weeks (after physician evaluation).

Layer 5 — procedures: Lasers, microdermabrasion (dermatology evaluation).

Layer 6 — diet/lifestyle: Antioxidant diet, sleep, hormone balance (variability with pregnancy, perimenopausal melasma).

Who fits

Widespread chronic melasma: Oral tranexamic acid as first-line option.

Localized melasma: Topical as first-line option.

Procedure-ineligible populations: Difficulty with procedures due to pregnancy, allergy, cost. Tranexamic acid as alternative.

Post-procedure recurrence prevention: Procedure + topical tranexamic acid maintenance matrix.

Hormonal melasma: Pregnancy, contraceptives, perimenopausal melasma. With hormonal variability assessment.

Daily guide

Step 1 — UV protection: SPF 30+ daily. Foundation of all melasma treatment.

Step 2 — start topical: Tranexamic acid 5% or other option twice daily for 8~12 weeks.

Step 3 — assess effect: Photo comparison after 12 weeks. Add oral if effect weak.

Step 4 — oral option: 250 mg twice daily for 12 weeks after physician evaluation. VTE risk assessment essential.

Step 5 — maintenance: Maintain topical tranexamic acid after effect. Continue UV protection.

Diet/lifestyle: Antioxidant diet (berries, leafy greens, tea), sleep hygiene, stress management. Monitor hormonal variability.

Melasma is the interaction of UV, hormones, and inflammation. Tranexamic acid is a tool to untangle one knot of that interaction. No treatment lasts without UV protection as the foundation.